Search Results

GE HealthCare announced its Venue Family point-of-care ultrasound systems will now feature Caption Guidance, artificial intelligence -driven technology that provides real-time guidance to users for capturing diagnostic-quality cardiac images.

Fractyl Health, Inc. announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, and Dr. Timothy Kieffer, CSO of Fractyl Health, will participate in a virtual fireside chat at the upcoming Piper Sandler 2nd Annual Virtual Obesity Day on Wednesday, June 26, 2024 at 9:30 a.m. EDT.

Vistagen announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace.

In a strategic move that could reshape the understanding of long COVID and chronic Lyme disease, the Massachusetts Institute of Technology has forged a partnership with Movano Health for its MAESTRO study to harness the medical grade continuous health monitoring capabilities of Movano’s Evie Ring.

Sinaptica Therapeutics, Inc. today announced that it has been selected to join StartUp Health’s Alzheimer’s Moonshot.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces the results of the Tender Offer, as set out in the Shareholder circular published by the Company on 20 May 2024.

Fractyl Health, Inc. announced that it will accelerate its REMAIN-1 clinical study, which is evaluating Revita’s efficacy in maintaining weight loss following the discontinuation of GLP-1 therapy.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets that will provide Nestlé Health Science with full VOWST product and related intellectual property rights.

PureTech Health plc is pleased to announce that at the General Meeting of the Company held at 11:00 a.m. New York City time at the Company’s offices at 6 Tide Street, Boston, Massachusetts, 02210, United States, the proposed Special Resolution as set out in the Circular containing the Notice of General Meeting circulated to Shareholders and published on 20 May 2024 was duly passed.

Observational studies to focus on patients with addiction and end-of-life distress pending formal approval and permitting from Thai health authorities